<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:media="http://search.yahoo.com/mrss/"
     xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>MTIMES Global - Financial, Corporate &amp; Market News</title>
    <link>https://mtimes.net</link>
    <description>Real-time English, Japanese, and Chinese financial news, South Korean stock market analysis, corporate governance, and global tech supply chain intelligence.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 02 Nov 2026 06:39:11 GMT</lastBuildDate>
    <atom:link href="https://mtimes.net/rss.xml" rel="self" type="application/rss+xml" />
    <atom:link href="https://pubsubhubbub.appspot.com/" rel="hub" />
    <copyright>Copyright 2026 MTIMES Global. All rights reserved.</copyright>
    <item>
      <title>Suprema: Moving Beyond Facial Recognition to Intelligent Spaces, Says Small Insight Research</title>
      <link>https://mtimes.net/article/1413</link>
      <guid isPermaLink="true">https://mtimes.net/article/1413</guid>
      <pubDate>Sun, 01 Nov 2026 23:10:21 GMT</pubDate>
      <description>Small Insight Research highlighted Suprema&apos;s robust growth in overseas markets driven by its high-margin biometric access control business, alongside its strategic expansion into AI video surveillance, integrated monitoring, and robot security.</description>
      <category>Headline</category>
      <author>editorial@mtimes.net (Kim Moo-jin Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EC%8A%88%ED%94%84%EB%A6%AC%EB%A7%88%20%EA%B8%B0%EC%82%AC%20%EC%9D%B4%EB%AF%B8%EC%A7%80-800x600.webp" medium="image" />
    </item>
    <item>
      <title>KOSDAQ under siege: Calls mount for short-selling ban and growth-tailored regulations</title>
      <link>https://mtimes.net/article/1410</link>
      <guid isPermaLink="true">https://mtimes.net/article/1410</guid>
      <pubDate>Sun, 01 Nov 2026 03:17:17 GMT</pubDate>
      <description>As the KOSDAQ index flirts with the 720 threshold, market participants are increasingly demanding regulatory overhauls, including a ban on short-selling, the abolition of investor-caution designations, and the relaxation of earnings-loss rules tailored to R&amp;D-heavy growth companies.</description>
      <category>Markets</category>
      <author>editorial@mtimes.net (Park Hae-soo Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EC%BD%94%EC%8A%A4%EB%8B%A5%20%EA%B5%AD%EB%AF%BC%EC%B2%AD%EC%9B%90-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Binance Suffers $6B Hack and Massive Customer Outflows; S.Korea Financial Watchdog Calls Emergency Meeting</title>
      <link>https://mtimes.net/article/1415</link>
      <guid isPermaLink="true">https://mtimes.net/article/1415</guid>
      <pubDate>Sun, 01 Nov 2026 23:52:52 GMT</pubDate>
      <description>Following a record $6 billion security breach at Binance, South Korea&apos;s Financial Services Commission has convened an emergency meeting with domestic exchanges to review customer asset protection measures, as questions mount over cold wallet storage thresholds.</description>
      <category>Markets</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EB%B0%94%EC%9D%B4%EB%82%B8%EC%8A%A4-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Is Wall Street’s 100% Win Rate Ahead of the Midterms Real? Analyzing the Statistics</title>
      <link>https://mtimes.net/article/1412</link>
      <guid isPermaLink="true">https://mtimes.net/article/1412</guid>
      <pubDate>Sun, 01 Nov 2026 23:00:41 GMT</pubDate>
      <description>As Wall Street faces recent volatility—highlighted by a sharp 7.2% drop in the Philadelphia Semiconductor Index—market attention turns to the historical pattern surrounding U.S. midterm elections. While data shows a seemingly flawless 100% win rate for U.S. equities from October of a midterm year through June of the following year, a closer look reveals statistical nuances worth noting.</description>
      <category>Finance &amp; Securities</category>
      <author>editorial@mtimes.net (Lee Kyung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EB%A9%94%EB%A5%B4%20%EB%A9%94%EC%9D%B8%EC%9D%B4%EB%AF%B8%EC%A7%80-400x300.webp" medium="image" />
    </item>
    <item>
      <title>South Korea’s October Exports Surge 34% Excluding Semiconductors, Led by Double-Digit Growth in Electrical Equipment and Cosmetics</title>
      <link>https://mtimes.net/article/1414</link>
      <guid isPermaLink="true">https://mtimes.net/article/1414</guid>
      <pubDate>Sun, 01 Nov 2026 23:42:41 GMT</pubDate>
      <description>Exports of non-semiconductor items jumped 34% year-on-year in October, powered by a record-breaking performance in electrical equipment and robust gains across cosmetics and bio-health. While stellar chip demand led the headline numbers, 18 of South Korea&apos;s top 20 export categories registered growth.</description>
      <category>Industry</category>
      <author>editorial@mtimes.net (Song Jung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EB%B6%80%EC%82%B0%EC%8B%A0%ED%95%AD%2004-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Even &apos;Value-Up&apos; Disclosures Fail to Lift Low-PBR Stocks as Major Conglomerates Make the List</title>
      <link>https://mtimes.net/article/1417</link>
      <guid isPermaLink="true">https://mtimes.net/article/1417</guid>
      <pubDate>Mon, 02 Nov 2026 01:32:21 GMT</pubDate>
      <description>The Korea Exchange has published a list of 151 listed companies suffering from prolonged low price-to-book ratios, featuring numerous blue-chip heavyweights despite ongoing corporate governance reform efforts.</description>
      <category>Finance &amp; Securities</category>
      <author>editorial@mtimes.net (Lee Kyung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%ED%95%9C%EA%B5%AD%EA%B1%B0%EB%9E%98%EC%86%8C-1-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Anthropic Expands AI Business into Drug Discovery, from Antibody Optimization to Clinical Support</title>
      <link>https://mtimes.net/article/1408</link>
      <guid isPermaLink="true">https://mtimes.net/article/1408</guid>
      <pubDate>Sun, 01 Nov 2026 00:44:02 GMT</pubDate>
      <description>Anthropic is aggressively expanding into the life sciences sector, moving beyond supplying research-grade AI to pharmaceutical firms to directly participating in drug discovery with its own research organization and laboratories. The company plans to deploy its Claude model across target design, experimental data analysis, and clinical trial planning.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Song Jung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/dario_amodei_techcrunch_2023-400x300.webp" medium="image" />
    </item>
    <item>
      <title>KOSDAQ in crisis at 700 mark... Why couldn&apos;t the upward trend be maintained?</title>
      <link>https://mtimes.net/article/1406</link>
      <guid isPermaLink="true">https://mtimes.net/article/1406</guid>
      <pubDate>Sat, 31 Oct 2026 06:20:14 GMT</pubDate>
      <description>After hitting the 1,200-point mark in April, the KOSDAQ index has plunged by more than 40% in six months, widening its performance gap with the KOSPI to 57.7 percentage points. Structural issues, including the migration of blue-chip companies, earnings polarization, and capital flight toward large-cap stocks, continue to weigh on the index 30 years after its inception.</description>
      <category>Markets</category>
      <author>editorial@mtimes.net (Choi Jun-hyuk Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EC%BD%94%EC%8A%A4%EB%8B%A5700-400x300.webp" medium="image" />
    </item>
    <item>
      <title>South Korean Battery Makers Pivot to LFP and ESS Amid Evolving Demand</title>
      <link>https://mtimes.net/article/1409</link>
      <guid isPermaLink="true">https://mtimes.net/article/1409</guid>
      <pubDate>Sun, 01 Nov 2026 00:45:09 GMT</pubDate>
      <description>POSCO Future M and LG Energy Solution have signed a preliminary agreement to supply 720,000 tons of cathode and anode materials over seven years, marking a strategic shift toward energy storage systems and affordable electric vehicles.</description>
      <category>Industry</category>
      <author>editorial@mtimes.net (Park Hae-soo Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%ED%8F%AC%EC%8A%A4%EC%BD%94%ED%93%A8%EC%B2%98%EC%97%A0-400x300.webp" medium="image" />
    </item>
    <item>
      <title>South Korea Pledges ₩5 Trillion to Boost AI Adoption Among Small Manufacturers</title>
      <link>https://mtimes.net/article/1407</link>
      <guid isPermaLink="true">https://mtimes.net/article/1407</guid>
      <pubDate>Sun, 01 Nov 2026 00:27:26 GMT</pubDate>
      <description>Seoul aims to scale up AI adoption among small and medium-sized manufacturing enterprises tenfold by 2030, deploying physical AI and manufacturing robots to bridge a widening technological gap with conglomerates.</description>
      <category>Industry</category>
      <author>editorial@mtimes.net (Lee Kyung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EC%A4%91%EC%86%8C%EB%B2%A4%EC%B2%98%EA%B8%B0%EC%97%85%EB%B6%80-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Telecom Base Stations Evolve Into AI Infrastructure: A New Semiconductor Market Beyond Data Centers</title>
      <link>https://mtimes.net/article/1394</link>
      <guid isPermaLink="true">https://mtimes.net/article/1394</guid>
      <pubDate>Fri, 30 Oct 2026 00:15:41 GMT</pubDate>
      <description>As telecom base stations begin to handle AI computations alongside traditional voice and data traffic, major tech firms like Nvidia, Nokia, and Samsung Electronics are accelerating the development of AI-RAN technologies. This shift could potentially expand the market for GPUs and server memory far beyond traditional data centers.</description>
      <category>Industry</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/0-25-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Big Insight: Assessing the Market Impact of the September U.S. CPI Report</title>
      <link>https://mtimes.net/article/1241</link>
      <guid isPermaLink="true">https://mtimes.net/article/1241</guid>
      <pubDate>Thu, 15 Oct 2026 00:54:49 GMT</pubDate>
      <description>The U.S. September Consumer Price Index (CPI) report has rattled financial markets, as &quot;sticky&quot; core inflation pressures raise the possibility of an earlier-than-expected interest rate hike by the Federal Reserve.</description>
      <category>Finance &amp; Securities</category>
      <author>editorial@mtimes.net (Park Hae-soo Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EB%A9%94%EB%A5%B4%20%EB%A9%94%EC%9D%B8%EC%9D%B4%EB%AF%B8%EC%A7%80-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Mezzion Pharma Targets First-ever Fontan Treatment Approval, Leveraging Clinical Expertise for Global Commercialization</title>
      <link>https://mtimes.net/article/1214</link>
      <guid isPermaLink="true">https://mtimes.net/article/1214</guid>
      <pubDate>Mon, 12 Oct 2026 23:51:43 GMT</pubDate>
      <description>South Korean biotech firm Mezzion Pharma is expanding its pivotal Phase 3 trial for Udenafil to Europe as it moves toward a potential 2027 FDA filing, with peak annual U.S. sales estimated at $3 billion.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Song Jung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/file_000000009a3c8209814fd10b9cfba476-400x300.webp" medium="image" />
    </item>
    <item>
      <title>HLB Therapeutics CEO An Ki-hong: “RGN-259 Set to Become First-Line Choice for Neurotrophic Keratitis”</title>
      <link>https://mtimes.net/article/1162</link>
      <guid isPermaLink="true">https://mtimes.net/article/1162</guid>
      <pubDate>Tue, 06 Oct 2026 22:55:31 GMT</pubDate>
      <description>HLB Therapeutics CEO An Ki-hong emphasized that the superior convenience and safety profile of RGN-259 will drive its adoption as a primary treatment for neurotrophic keratitis (NK), with top-line results from the SEER-2 global Phase 3 clinical trial expected by mid-November.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/IMG_5281-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Global Phase 3 Watch: HLB Therapeutics Eyes $1.7B U.S. Neurotrophic Keratitis Market with November RGN-259 Readout</title>
      <link>https://mtimes.net/article/1146</link>
      <guid isPermaLink="true">https://mtimes.net/article/1146</guid>
      <pubDate>Mon, 05 Oct 2026 21:42:37 GMT</pubDate>
      <description>HLB Therapeutics is preparing for a make-or-break moment in November, as it awaits the top-line results of its U.S. Phase 3 &quot;SEER-2&quot; trial for the neurotrophic keratitis (NK) treatment candidate RGN-259. The company aims to challenge the U.S. market dominance of Dompé’s &quot;Oxervate,&quot; leveraging the logistical advantages of a shelf-stable, short-term treatment regimen.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/1000172684-400x300.webp" medium="image" />
    </item>
    <item>
      <title>[K-Bio Global Phase 3] Fred Kim, Head of AriBio US: &quot;AR1001 Aims to Become the First-Line Therapy for Early Alzheimer’s&quot;</title>
      <link>https://mtimes.net/article/1141</link>
      <guid isPermaLink="true">https://mtimes.net/article/1141</guid>
      <pubDate>Sat, 03 Oct 2026 02:18:40 GMT</pubDate>
      <description>AriBio’s U.S. division head, Fred Kim, outlined the company’s ambition to position its oral Alzheimer’s candidate, AR1001, as a first-line treatment, with global Phase 3 trial results set for release in November 2026.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Song Jung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/20261001_105713-1-400x300.webp" medium="image" />
    </item>
    <item>
      <title>ARBIOW&apos;s AR1001 Aims for November Milestone as Commercialization Pace Quickens</title>
      <link>https://mtimes.net/article/1135</link>
      <guid isPermaLink="true">https://mtimes.net/article/1135</guid>
      <pubDate>Fri, 02 Oct 2026 08:03:16 GMT</pubDate>
      <description>ArisBio is gearing up for the pivotal November release of its Phase 3 global clinical trial results for its oral Alzheimer&apos;s treatment candidate, AR1001, setting its sights on U.S. FDA approval by 2028 and a 1 trillion won revenue milestone by 2030.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Song Jung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/20261001_105933-400x300.webp" medium="image" />
    </item>
    <item>
      <title>KOSPI Edges Up, Yet 7 in 10 Stocks Fall as Semiconductor Concentration Deepens</title>
      <link>https://mtimes.net/article/1128</link>
      <guid isPermaLink="true">https://mtimes.net/article/1128</guid>
      <pubDate>Fri, 02 Oct 2026 00:05:00 GMT</pubDate>
      <description>While the KOSPI finished September in positive territory, the broader market suffered a severe breadth contraction as heavyweights Samsung Electronics and SK hynix propped up the index while nearly 70% of listed issues declined.</description>
      <category>Markets</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/1-44-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Beyond Micron’s Strong Earnings: Long-Term Supply Contracts Rush in Through 2031</title>
      <link>https://mtimes.net/article/1117</link>
      <guid isPermaLink="true">https://mtimes.net/article/1117</guid>
      <pubDate>Wed, 30 Sep 2026 23:01:34 GMT</pubDate>
      <description>Behind Micron’s robust quarterly earnings lies an even stronger industry signal, as hyperscalers and AI data centers rush to lock in memory supply agreements stretching all the way to 2031.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%A0-400x300.webp" medium="image" />
    </item>
    <item>
      <title>AI Works Even When the App is Closed: Big Tech Shifts Focus to Persistent Autonomous Agents</title>
      <link>https://mtimes.net/article/1113</link>
      <guid isPermaLink="true">https://mtimes.net/article/1113</guid>
      <pubDate>Wed, 30 Sep 2026 09:33:40 GMT</pubDate>
      <description>Global technology giants are moving beyond conversational chatbots to always-on autonomous AI agents capable of executing tasks, scheduling, and data analysis in the background without user intervention.</description>
      <category>Industry</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/29-400x300.webp" medium="image" />
    </item>
    <item>
      <title>HanAll Biopharma’s Batoclimab Wins Approval in China; Next-Gen Antibody Progresses to Global Phase 3 Trials</title>
      <link>https://mtimes.net/article/1348</link>
      <guid isPermaLink="true">https://mtimes.net/article/1348</guid>
      <pubDate>Mon, 26 Oct 2026 21:48:11 GMT</pubDate>
      <description>HanAll Biopharma’s autoimmune disease treatment batoclimab has received marketing approval in China following successful Phase 3 clinical trials, paving the way for milestone payments and sales royalties. Meanwhile, its next-generation candidate, imireprovat (IMVT-1402), is undergoing global Phase 3 trials for generalized myasthenia gravis, with early therapeutic responses also observed in rheumatoid arthritis.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Song Jung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%ED%95%9C%EC%98%AC%EB%B0%94%EC%9D%B4%EC%98%A4%ED%8C%8C%EB%A7%88_%EB%A1%9C%EA%B3%A0_4%EB%8C%803_%EC%97%AC%EB%B0%B1-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Hanhan Breaches US Warship Market with Philly Shipyard Acquisition and $5B Expansion Plan</title>
      <link>https://mtimes.net/article/1420</link>
      <guid isPermaLink="true">https://mtimes.net/article/1420</guid>
      <pubDate>Mon, 02 Nov 2026 04:47:16 GMT</pubDate>
      <description>Hanwha has secured its first U.S. Navy contract to build medium landing ships, marking a major milestone as a South Korean shipbuilder enters the domestic-only U.S. naval market through strategic local acquisitions and advanced manufacturing technology.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%ED%95%9C%ED%99%94%EC%A1%B0%EC%84%A0%EC%86%8C-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Hanmi Semiconductor Faces Earnings Miss Despite HBM Boom</title>
      <link>https://mtimes.net/article/1396</link>
      <guid isPermaLink="true">https://mtimes.net/article/1396</guid>
      <pubDate>Fri, 30 Oct 2026 02:34:19 GMT</pubDate>
      <description>Despite maintaining a robust operating margin above 50%, Hanmi Semiconductor’s third-quarter results fell nearly 30% short of market expectations, sparking a significant sell-off in its stock.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%ED%95%9C%EB%AF%B8%EB%B0%98%EB%8F%84%EC%B2%B4-1-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Samsung Electronics Slumps as Shareholder Return Plan Disappoints Investors; KOSPI Falls Back Below 6,000</title>
      <link>https://mtimes.net/article/1382</link>
      <guid isPermaLink="true">https://mtimes.net/article/1382</guid>
      <pubDate>Thu, 29 Oct 2026 05:10:49 GMT</pubDate>
      <description>Despite posting record-high quarterly earnings, Samsung Electronics saw its shares tumble as the company deferred specific details on its share buyback and cancellation program until next January, sparking a wave of sell-offs following its earnings call.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/3-14-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Alteogen’s SC Technology Gains Traction as Keytruda SC Sales Top $830 Million</title>
      <link>https://mtimes.net/article/1398</link>
      <guid isPermaLink="true">https://mtimes.net/article/1398</guid>
      <pubDate>Fri, 30 Oct 2026 05:30:59 GMT</pubDate>
      <description>Alteogen&apos;s subcutaneous (SC) delivery technology is driving significant revenue growth for Merck&apos;s Keytruda SC, with quarterly sales surging 79% to exceed $830 million.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Song Jung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EC%95%8C%ED%85%8C%EC%98%A4%EC%A0%A0-1-400x300-400x300.webp" medium="image" />
    </item>
    <item>
      <title>SK hynix Secures Supply Through 2029 as Operating Margin Approaches 80%</title>
      <link>https://mtimes.net/article/1363</link>
      <guid isPermaLink="true">https://mtimes.net/article/1363</guid>
      <pubDate>Wed, 28 Oct 2026 02:32:00 GMT</pubDate>
      <description>SK hynix has effectively pre-sold its DRAM and HBM output through 2029, bolstered by a surge in AI data center investment. The company reported a record-breaking operating margin near 80%, fueled by long-term contracts with 14 major global tech clients.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/SK%ED%95%98%EC%9D%B4%EB%8B%89%EC%8A%A4-400x300.webp" medium="image" />
    </item>
    <item>
      <title>SanDisk Rewards Shareholders on AI Storage Boom with $5B Buyback</title>
      <link>https://mtimes.net/article/1421</link>
      <guid isPermaLink="true">https://mtimes.net/article/1421</guid>
      <pubDate>Mon, 02 Nov 2026 05:15:22 GMT</pubDate>
      <description>Data center revenue surges 61% quarter-on-quarter, accounting for 43.5% of total sales as SanDisk posts stellar fiscal Q1 results driven by artificial intelligence infrastructure demand.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Song Jung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/Screenshot_20261102_141159_ChatGPT-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Even a $4.8B Acquisition Wasn’t Enough: Why BioMarin Chose Hanmi and GC Biopharma</title>
      <link>https://mtimes.net/article/1402</link>
      <guid isPermaLink="true">https://mtimes.net/article/1402</guid>
      <pubDate>Fri, 30 Oct 2026 08:34:53 GMT</pubDate>
      <description>Despite securing a blockbuster oral treatment through its multi-billion-dollar acquisition of Amicus Therapeutics, U.S. rare-disease specialist BioMarin has licensed a Phase 1/2 Fabry disease candidate jointly developed by Hanmi Pharmaceutical and GC Biopharma to target a broader patient demographic and challenge established intravenous therapies.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/%EB%B0%94%EC%9D%B4%EC%98%A4%EB%A7%88%EB%A6%B0-400x300.webp" medium="image" />
    </item>
    <item>
      <title>Multibillion-Won Bet on JYP? Doubts Linger Over Nexroc’s Spree of Takeover Bids</title>
      <link>https://mtimes.net/article/1388</link>
      <guid isPermaLink="true">https://mtimes.net/article/1388</guid>
      <pubDate>Thu, 29 Oct 2026 09:56:27 GMT</pubDate>
      <description>An obscure overseas investment group, Nexroc, has announced plans to acquire 14 companies, including K-pop agency JYP Entertainment and Japan&apos;s Avex, while proposing a tender offer for up to 50% of JYP. However, with no official negotiations initiated, unverified financial disclosures, and regulatory scrutiny mounting over its funding capabilities, market skepticism is intensifying.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Kim Jeong-eun Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/JYP%EC%97%94%ED%84%B0-400x300.webp" medium="image" />
    </item>
    <item>
      <title>LG Electronics pivots toward automotive and data centers as business portfolio shifts</title>
      <link>https://mtimes.net/article/1384</link>
      <guid isPermaLink="true">https://mtimes.net/article/1384</guid>
      <pubDate>Thu, 29 Oct 2026 07:08:14 GMT</pubDate>
      <description>LG Electronics&apos; vehicle components division posts record third-quarter earnings, while cumulative orders for data center cooling solutions surpass 3 trillion won, accelerating the company&apos;s strategic shift toward business-to-business (B2B) markets and reducing its reliance on traditional home appliances.</description>
      <category>Corporate</category>
      <author>editorial@mtimes.net (Lee Kyung-hee Reporter)</author>
      <media:content url="https://media.markettimes.co.kr/LG%EC%A0%84%EC%9E%90-400x300.webp" medium="image" />
    </item>
  </channel>
</rss>